1. Home
  2. IBRX vs ENVX Comparison

IBRX vs ENVX Comparison

Compare IBRX & ENVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ImmunityBio Inc.

IBRX

ImmunityBio Inc.

HOLD

Current Price

$2.32

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Logo Enovix Corporation

ENVX

Enovix Corporation

HOLD

Current Price

$7.78

Market Cap

2.4B

Sector

Miscellaneous

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBRX
ENVX
Founded
2014
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Industrial Machinery/Components
Sector
Health Care
Miscellaneous
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.4B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
IBRX
ENVX
Price
$2.32
$7.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
7
Target Price
$9.83
$17.14
AVG Volume (30 Days)
9.5M
8.0M
Earning Date
11-04-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$82,555,000.00
$30,273,000.00
Revenue This Year
$629.94
$44.18
Revenue Next Year
$109.91
$212.03
P/E Ratio
N/A
N/A
Revenue Growth
1025.95
45.98
52 Week Low
$1.83
$5.27
52 Week High
$5.16
$16.49

Technical Indicators

Market Signals
Indicator
IBRX
ENVX
Relative Strength Index (RSI) 58.44 36.66
Support Level $2.05 $7.27
Resistance Level $2.18 $8.11
Average True Range (ATR) 0.13 0.57
MACD 0.03 -0.02
Stochastic Oscillator 83.00 35.02

Price Performance

Historical Comparison
IBRX
ENVX

About IBRX ImmunityBio Inc.

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.

About ENVX Enovix Corporation

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

Share on Social Networks: